PHARMAC widens access to two cancer drugs
This article was originally published in Scrip
New Zealand's regulator, PHARMAC, has approved wider funding for two cancer drugs – rituximab and docetaxel – in a bid to improve cancer treatment across the country.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.